Pulse Biosciences Appoints Mitchell E. Levinson as Chief Strategy Officer

Pulse Biosciences Inc., a bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, has appointed Mitchell E. Levinson to the newly created role of chief strategy officer, effective immediately, in addition to the continuation of his role as a member of the Pulse Biosciences Board of Directors.
 
“As a board member and medical device industry veteran with a track record of successfully bringing new technologies and products to market across a variety of medical specialties, Mitch’s insights have benefitted Pulse Biosciences for over five years,” said Darrin Uecker, president and CEO of Pulse Biosciences. “We are thrilled to add him to the executive leadership team at this critical time as we continue to build our dermatology business and accelerate our expansion into a multi-specialty company by leveraging our existing CellFX platform with CellFX CloudConnect. We believe Mitch is uniquely qualified to spearhead our expansion efforts with his broad experience and skillset.”
 
Levinson has more than 30 years of experience developing and launching novel medical device technologies across multiple medical disciplines, including dermatology, wound care, surgery, diagnostics, otolaryngology, microbiology, neurology, OB/GYN, patient monitoring and digital health. Most recently, he co-founded and served as startup CEO for Cerebrotech Medical Systems, where he led the development of a novel brain monitor. Levinson was the first employee and startup CEO for Zeltiq Aesthetics, the CoolSculpting company, acquired by Allergan in 2017. Prior to Zeltiq, he held executive R&D positions at Thermage and BioSurgical Corporation. Levinson currently sits on the boards of directors for several medical technology startup companies. He is an inventor on 50 issued and numerous pending U.S. patents.

Levinson earned a bachelor of science degree in mechanical engineering from University of California at San Diego and holds a master of science degree in computer systems from the University of Phoenix.
 
“As one of Pulse Biosciences’ early board members, I have had the privilege of working closely with the board and management team over the years to develop the company’s strategy and vision for our highly differentiated and proprietary NPS technology,” said Levinson. “I am very excited to be joining the executive team at this important time in the company’s growth as we pursue the use of our NPS technology beyond dermatology, where I am confident we can offer additional safe and effective medical interventions to improve patient care and address unmet needs for healthcare providers.”
 
Pulse Biosciences is a bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The company’s proprietary Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of applications for which an optimal solution remains unfulfilled. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model.